The Genomics Shared Resource (GSR) is a state-of-the-art genomics facility dedicated to providing the latest genomic research tools at low cost. The primary goal of GSR is to facilitate high-impact cancer research by Stanford Cancer Institute (SCI) members by providing genetic and genomic-based tools. This goal is accomplished by providing SCI members with unencumbered, comprehensive and cost-effective access to cutting-edge genomics technologies and all the necessary services, expertise and scientific support necessary to utilize these technologies to further cancer research. Major GSR technologies and services include: high-throughput sequencing, microarray-based analysis, real-time quantitative PCR, and multiplex single-molecule analysis. Expert guidance with the use of each technology is also provided throughout the entire experimental process, including guidance with experimental design, data analysis, data archiving and publication. The resources of the Stanford Functional Genomics Facility (SFGF), Protein and Nucleic Acid Facility (PAN), the Genome Sequencing Service Center (GSSC) and Genetics Bioinformatics Service Center (GBSC) have combined under the leadership of John Coller, PhD, as Director of the GSR, to provide the full spectrum of services with a total combined operating budget of $4.3M. Michael Eckart, PhD (PAN) co-directs the GSR. Arend Sidow, PhD, is the faculty advisor. Since 2009 over 130 SCI members have used the shared resource, representing all program affiliations. Future plans include expanding cancer specific bioinformatics support with the addition of one full time bioinformatician, upgrading high-throughput sequencing instrumentation, and continuing to expand sample and library preparation services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-13
Application #
9936141
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
13
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Pollom, Erqi L; Fujimoto, Dylann K; Han, Summer S et al. (2018) Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival. J Radiat Res 59:i11-i18
Nørgaard, Caroline Holm; Jakobsen, Lasse Hjort; Gentles, Andrew J et al. (2018) Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. PLoS One 13:e0193249
Im, Hogune; Rao, Varsha; Sridhar, Kunju et al. (2018) Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells. Leuk Lymphoma 59:2952-2962
Huang, Min; Zhu, Li; Garcia, Jacqueline S et al. (2018) Brd4 regulates the expression of essential autophagy genes and Keap1 in AML cells. Oncotarget 9:11665-11676
Chiou, Shin-Heng; Dorsch, Madeleine; Kusch, Eva et al. (2018) Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Sci Rep 8:14008
Breslow, David K; Hoogendoorn, Sascha; Kopp, Adam R et al. (2018) A CRISPR-based screen for Hedgehog signaling provides insights into ciliary function and ciliopathies. Nat Genet 50:460-471
Chu, Lisa W; Till, Cathee; Yang, Baiyu et al. (2018) Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Mol Carcinog 57:462-466
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442

Showing the most recent 10 out of 322 publications